Toth Financial Advisory Corp Grows Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Toth Financial Advisory Corp boosted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 34.6% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 5,500 shares of the company’s stock after buying an additional 1,413 shares during the quarter. Toth Financial Advisory Corp’s holdings in Neurocrine Biosciences were worth $759,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the business. First Horizon Advisors Inc. grew its position in Neurocrine Biosciences by 10.5% in the 4th quarter. First Horizon Advisors Inc. now owns 782 shares of the company’s stock valued at $103,000 after acquiring an additional 74 shares during the last quarter. Quadrant Capital Group LLC grew its position in Neurocrine Biosciences by 3.9% in the 4th quarter. Quadrant Capital Group LLC now owns 2,075 shares of the company’s stock valued at $273,000 after acquiring an additional 78 shares during the last quarter. Envestnet Portfolio Solutions Inc. grew its position in Neurocrine Biosciences by 3.2% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 2,530 shares of the company’s stock valued at $333,000 after acquiring an additional 78 shares during the last quarter. Sunbelt Securities Inc. grew its position in Neurocrine Biosciences by 34.3% in the 3rd quarter. Sunbelt Securities Inc. now owns 325 shares of the company’s stock valued at $37,000 after acquiring an additional 83 shares during the last quarter. Finally, Balentine LLC grew its position in Neurocrine Biosciences by 4.0% in the 4th quarter. Balentine LLC now owns 2,316 shares of the company’s stock valued at $305,000 after acquiring an additional 89 shares during the last quarter. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Stock Up 2.5 %

Shares of NASDAQ:NBIX opened at $137.67 on Friday. Neurocrine Biosciences, Inc. has a 52-week low of $93.02 and a 52-week high of $148.37. The stock has a market cap of $13.86 billion, a price-to-earnings ratio of 37.93 and a beta of 0.36. The business has a 50-day moving average price of $137.34 and a 200-day moving average price of $135.72.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Wednesday, May 1st. The company reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.04 by ($0.62). Neurocrine Biosciences had a return on equity of 17.45% and a net margin of 18.65%. The firm had revenue of $515.30 million during the quarter, compared to analysts’ expectations of $512.21 million. As a group, equities analysts anticipate that Neurocrine Biosciences, Inc. will post 4.19 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Stephen A. Sherwin sold 40,000 shares of the firm’s stock in a transaction dated Wednesday, May 29th. The stock was sold at an average price of $133.46, for a total transaction of $5,338,400.00. Following the sale, the director now directly owns 26,504 shares of the company’s stock, valued at $3,537,223.84. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, Director Stephen A. Sherwin sold 40,000 shares of the firm’s stock in a transaction dated Wednesday, May 29th. The stock was sold at an average price of $133.46, for a total transaction of $5,338,400.00. Following the sale, the director now directly owns 26,504 shares of the company’s stock, valued at $3,537,223.84. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Eric Benevich sold 19,818 shares of the firm’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $133.36, for a total value of $2,642,928.48. Following the sale, the insider now directly owns 40,778 shares in the company, valued at $5,438,154.08. The disclosure for this sale can be found here. Insiders have sold a total of 88,697 shares of company stock valued at $11,975,615 over the last ninety days. Company insiders own 4.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. Canaccord Genuity Group upped their price objective on Neurocrine Biosciences from $154.00 to $164.00 and gave the company a “buy” rating in a research report on Thursday, May 2nd. Cantor Fitzgerald reissued an “overweight” rating and set a $155.00 price target on shares of Neurocrine Biosciences in a research report on Wednesday, April 10th. Citigroup increased their price target on Neurocrine Biosciences from $140.00 to $150.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. Oppenheimer increased their price target on Neurocrine Biosciences from $200.00 to $216.00 and gave the stock an “outperform” rating in a research report on Thursday, May 2nd. Finally, HC Wainwright upped their price objective on Neurocrine Biosciences from $150.00 to $160.00 and gave the stock a “buy” rating in a research note on Thursday, May 2nd. Six research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $152.00.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.